The $83bn question: Will orphan drugs get too big for their boots?
This article was originally published in Scrip
For the past seven years, 28 February has been Rare Disease Day, and the growing public profile of this date mirrors the rising fortunes of orphan drugs, which now account for nearly 15% of the global prescription pharma market.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.